Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs
, , , , , et
20 août 2020
À propos de cet article
Publié en ligne: 20 août 2020
Pages: 45 - 55
Reçu: 29 avr. 2020
Accepté: 28 mai 2020
DOI: https://doi.org/10.2478/acm-2020-0006
Mots clés
© 2020 K Prso et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible